Autologous Induced Stem-Cell-Derived Retinal Cells for Macular Degeneration.

By E. Souied, J. Pulido, G. Staurenghi. New England Journal of Medicine, 2017

675 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Aging and aging-related diseases: from molecular mechanisms to interventions and treatments (2022, background): “In addition, treating AMD by transplanting RPE cells derived from skin fibroblast-generated pluripotent stem cells (iPSCs) improves the VFQ-25 score.(646) Many clinical trials have analyzed the role of antioxidative stress in AMD therapy and have shown a certain beneficial effect on the clinical pre”
Ethical and Safety Issues of Stem Cell-Based Therapy (2018, background): “Recently, clinical trial that investigated potential of autologous iPSC-RPE for the treatment of advanced neovascular age-related macular degeneration has been stopped [35].”
Gene therapy clinical trials worldwide to 2017: An update (2018, background): “Recently, it was reported that RIKEN has resumed this world‐first trial using iPS‐ derived retinal pigment epithelial cells, indicating a good safety profile 1 year following treatment.(158,159) Although proof‐of‐principal for combining somatic cell reprogramming with gene therapy for disease treatm”